Zijun Y. Xu‐Monette
The University of Texas MD Anderson Cancer Center(US)Duke University(US)Clinical Research Institute(US)Duke Institute for Health Innovation(US)Duke Medical Center(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, Viral-associated cancers and disorders, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone(2012)679 cited
- → MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program(2013)672 cited
- → PD-1 expression and clinical PD-1 blockade in B-cell lymphomas(2017)425 cited
- → Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients(2013)398 cited
- → Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study(2012)383 cited